Seeking Alpha

Laura-Mae Britton

View as an RSS Feed
View Laura-Mae Britton's Comments BY TICKER:
Latest  |  Highest rated
  • New Cancer Targets And Big Partnerships May Be Driving Huge Epizyme Valuation [View article]
    Hi Westcoaster,

    Thanks for your feedback, and great question!

    More often than not, companies will not release sales data from drugs that aren’t driving huge revenues so in the case of Zolina, there isn’t much data available data from Merck. For Istodax (romidepsin), sales increased more than three-fold from $15.8 million in 2010 at the product’s debut, to $50 million in 2012. Some of the rapid increases in sales can be attributed to the drug’s accelerated approval in 2011 to treat patients with peripheral T-cell lymphoma. However I should just mention that although HDACi’s and HMTi’s both target “epigenetic mechanisms”, their pathways are quite different and therefore the success or failure of Zolina and Istodax does not necessarily translate to Epizyme’s projected sale values.

    One other interesting tidbit is that Gloucester Pharmaceuticals developed Istodax to FDA approval for the first indication, second-line treatment for CTCL but was then acquired by Celgene for $340 million upfront and $300 million in future milestones payments.
    Sep 9 04:09 PM | Likes Like |Link to Comment
1 Comment